The Pediatric infectious disease journal
-
Pediatr. Infect. Dis. J. · Feb 2007
Randomized Controlled Trial Comparative StudyImmunogenicity of an inactivated hepatitis A vaccine in infants and young children.
Infants with passively transferred maternal antibody, born to mothers immune to hepatitis A virus (HAV), have a blunted response to hepatitis A (HA) vaccine. We compared HA vaccine immunogenicity among infants born to immune and susceptible mothers, vaccinated on different schedules. ⋯ HA vaccine is immunogenic among infants born to HA-susceptible mothers and those born to immune mothers and vaccinated beginning > or =12 months old. Passively transferred maternal antibody persists for at least 6 months and results in a blunted response to HA vaccination.
-
Pediatr. Infect. Dis. J. · Feb 2007
Case ReportsAtovaquone and azithromycin treatment for babesiosis in an infant.
An 8-month-old infant with cyanotic heart disease and transfusion-associated Babesia microti infection is reported here. At initial presentation, she was ill appearing, febrile and cyanotic. ⋯ The infant was treated successfully with a combination of oral azithromycin and atovaquone. This combination is an alternative to clindamycin and quinine for the treatment of children with babesiosis.
-
Pediatr. Infect. Dis. J. · Feb 2007
Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Two doses of measles-mumps-rubella (MMR) vaccine are recommended for elimination of these diseases in countries with universal mass vaccination; a 2-dose program is also likely to be required for elimination of childhood varicella and has recently been provisionally recommended in the United States. Given the overlap in MMR and varicella vaccination schedules, development of a combined vaccine appears logical and would facilitate the introduction of 2 doses of varicella vaccination in healthy children with no additional injections. ⋯ This experimental tetravalent MMRV vaccine appears well suited for use in national immunization programs in place of a second dose of MMR or MMR plus varicella in children who have already received a first dose of MMR.
-
Pediatr. Infect. Dis. J. · Feb 2007
Lack of value of procalcitonin for prediction of coronary aneurysms in Kawasaki disease.
We studied the clinical, biologic (white blood cells, C-reactive protein and procalcitonin) and echocardiographic findings in 18 children hospitalized for Kawasaki disease from January 1999 until February 2006 to determine if procalcitonin is a useful marker to predict coronary aneurysms. In our study, contrary to earlier reports, elevated procalcitonin was not correlated with development of coronary aneurysms.